drugset
drugset / Trial / NCT03720483

Inhaled NAC in Treatment of IPF

NCT03720483 ↗

Phase 1/2 Withdrawn University of Colorado, Denver
RandomizedCrossoverOpen-labelTreatment

Summary

This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.

Timeline

Start
2022-01
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule — Inhaled

Indications

idiopathic pulmonary fibrosis